Citi Downgrades Moonlake Immunotherapeutics (MLTX) to Sell
Tweet
Share
E-mailGet Alerts MLTX Hot Sheet
Price: $16.47 -0.18%
Rating Summary:
12 Buy, 4 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
12 Buy, 4 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Citi analyst Samantha Semenkow downgraded Moonlake Immunotherapeutics (NASDAQ: MLTX) from Neutral to Sell with a price target of $5.00.
For an analyst ratings summary and ratings history on Moonlake Immunotherapeutics click here. For more ratings news on Moonlake Immunotherapeutics click here.
Shares of Moonlake Immunotherapeutics closed at $9.82 yesterday.
You May Also Be Interested In
- Moonlake Immunotherapeutics (MLTX) PT Raised to $50 at H.C. Wainwright
- DA Davidson Downgrades Blaize Inc. (BZAI) to Neutral
- Goldman Sachs Downgrades Douglas AG (DOU:GR) to Sell
Create E-mail Alert Related Categories
DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
